AN2 Therapeutics, Inc. (ANTX) Analyst Estimates Annual - Discounting Cash Flows
ANTX
AN2 Therapeutics, Inc.
ANTX (NASDAQ)
Period Ending: 2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
Number of Analysts 1 1 1 1 0
Estimated Revenue
Low 389.9 217 72.7 33.2 0
Average 389.9 217 72.7 33.2 0
High 389.9 217 72.7 33.2 0
Estimated EBITDA
Low 0 0 0 0 0
Average 0 0 0 0 0
High 0 0 0 0 0
Estimated EBIT
Low 0 0 0 0 0
Average 0 0 0 0 0
High 0 0 0 0 0
Estimated Net Income
Low -30.82 -24.17 -27.5 -33.84 -51.73
Average -30.82 -24.17 -27.5 -33.84 -51.27
High -30.82 -24.17 -27.5 -33.84 -50.82
Estimated SGA Expenses
Low 0 0 0 0 0
Average 0 0 0 0 0
High 0 0 0 0 0
Estimated EPS
Low -1.02 -0.8 -0.91 -1.12 -1.73
Average -1.02 -0.8 -0.91 -1.12 -1.72
High -1.02 -0.8 -0.91 -1.12 -1.7
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program